Erratum: Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5.Antiviral research · 2023
   Article
2. Long non-coding RNA SNHG9 regulates viral replication in rhabdomyosarcoma cells infected with enterovirus D68Frontiers in microbiology · 2022
   Article
3. Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies.Antiviral research · 2019
   Article
4. EV-D68 infection in children with asthma exacerbation and pneumonia in Mexico City during 2014 autumn.Influenza and other respiratory viruses · 2016
   Article
5. Erratum: Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections.Reviews in medical virology · 2015
   Article

Corrections and comments

• Erratum for
  Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.